Glooko, a provider of remote patient monitoring and digital health solutions for diabetes, has acquired Monarch Medical Technologies, developer of the EndoTool glucose management system.

EndoTool is a software platform for inpatient insulin dosing and glycemic management. The acquisition expands Glooko’s connected care capabilities into inpatient glycemic management, complementing its strong foundation in outpatient diabetes management. The company hopes to build a single, integrated solution to support patients and clinicians for the full continuum of care.

“This acquisition represents a pivotal step in Glooko’s mission to transform diabetes management in every care setting,” said Mike Alvarez, CEO of Glooko. “We’ve built a strong foundation in the outpatient space—simplifying diabetes management for clinicians through unified device integration, EHR connectivity, and actionable insights. By adding Monarch’s proven inpatient insulin dosing expertise, we’re now uniquely positioned to deliver a truly comprehensive hospital-to-home solution that can improve outcomes, streamline workflows, and enhance patient safety. Looking ahead, this platform also creates opportunities to extend our leadership into primary care and advanced glycemic management, enabling us to serve patients and providers across the full continuum of care.”

The U.S. Food and Drug Administration (FDA)-cleared EndoTool helps clinicians optimize insulin dosing for hospitalized patients through a patient-specific algorithm to delivery precise, guideline-aligned insulin dosing in real time. This reduces the risk of low blood sugar and helps hospitals meet CMS quality measures.

Glooko’s platform is used by millions of patients and over 8,000 clinics globally. It aggregates data from more than 200 connected devices, including blood glucose meters, insulin pumps, continuous glucose monitors, and others. It aims to ease diabetes management for endocrinologists, primary care providers, nurses, diabetes educators, dietitians, and other clinicians by unifying data from a variety of devices onto a single platform, integrating with EHR workflows, and delivering actionable insights.

By adding EndoTool to its platform, Glooko can support acute care settings with precision insulin dosing software and support those patients further after discharge via its remote monitoring tools.

“Effective glycemic management doesn’t begin or end at the hospital doors. It’s a continuous journey,” said Mark Clements, M.D., Ph.D., chief medical and strategy officer at Glooko. “With new CMS quality measures and HEDIS metrics driving the need for consistent glucose control, connected solutions are no longer optional, they’re essential. By integrating EndoTool with Glooko’s outpatient platform, we believe we will be better able to ensure safer care transitions for people with diabetes, help hospitals meet quality and regulatory requirements, and deliver measurable improvements in patient outcomes across the continuum.”

In the near term, Glooko and Monarch Medical will operate their products as they do today to avoid disruption for users. Long-term, Glooko plans to integrate both offerings on one platform.

In October 2024, Glooko appointed Alvarez as CEO, and announced it had gained $100 million in Series F financing.